Charles River Laboratories International, Inc. Share Price
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
01:29:02 03/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 291.92 USD | +3.39% |
|
-1.56% | +45.62% |
| 21/08 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| 20/08 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
| Market Cap | 1.35TCr 1.16TCr 1.1TCr 998.02Cr 1.87TCr 1,27300Cr 1.88TCr 13TCr 5.03TCr 65TCr 5.06TCr 4.95TCr 2,13800Cr | P/E 2026 * |
75.5x | P/E 2027 * | 30.2x |
|---|---|---|---|---|---|
| Enterprise Value | 1.56TCr 1.35TCr 1.27TCr 1.15TCr 2.16TCr 1,47300Cr 2.17TCr 15TCr 5.82TCr 75TCr 5.85TCr 5.73TCr 2,47400Cr | EV / Sales 2026 * |
3.99x | EV / Sales 2027 * | 3.78x |
| Free-Float |
95.58% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Charles River Laboratories International, Inc.
| 1 day | +2.71% | ||
| 1 week | -1.78% | ||
| Current month | +0.56% | ||
| 1 month | +25.55% | ||
| 3 months | +65.83% | ||
| 6 months | +62.28% | ||
| Current year | +45.31% |
| 1 week | 280.91 | 303.3 | |
| 1 month | 228.01 | 303.3 | |
| Current year | 146.2 | 303.3 | |
| 1 year | 144.26 | 303.3 | |
| 3 years | 91.86 | 303.3 | |
| 5 years | 91.86 | 460.21 | |
| 10 years | 67.2 | 460.21 |
| Manager | Title | Age | Since |
|---|---|---|---|
Birgit Girshick
CEO | Chief Executive Officer | 56 | 05/05/2026 |
Glenn Coleman
DFI | Director of Finance/CFO | 58 | 06/04/2026 |
Namandje Bumpus
CTO | Chief Tech/Sci/R&D Officer | 45 | 12/01/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
James Foster
CHM | Chairman | 75 | 01/01/2000 |
Birgit Girshick
BRD | Director/Board Member | 56 | 05/05/2026 |
Martin MacKay
CHM | Chairman | 69 | 05/05/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 25/08/26 | Exercice | Director | 1,00,683 | 0.2090% | ||
| 19/08/26 | Don | Chief Executive Officer | -528 | 0.0011% | ||
| 19/08/26 | Exercice | Executive/Senior Manager | 6,117 | 0.0127% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.68% | -1.78% | +79.76% | +41.88% | 1.35TCr | ||
| +0.97% | -0.75% | +3.51% | +17.79% | 4.97TCr | ||
| +0.04% | -2.71% | +430.22% | +522.13% | 4.5TCr | ||
| +2.70% | +1.63% | +44.65% | +20.32% | 4.25TCr | ||
| +0.89% | -3.74% | +8.95% | +76.61% | 4.08TCr | ||
| -0.90% | -1.74% | +15.20% | +48.44% | 3.29TCr | ||
| +2.20% | +6.19% | - | - | 1.71TCr | ||
| +1.46% | -4.51% | +24.88% | +122.97% | 1.63TCr | ||
| +1.70% | -0.05% | +18.53% | +28.09% | 1.44TCr | ||
| -0.40% | -4.39% | -9.18% | -37.56% | 1.25TCr | ||
| Average | +1.17% | -2.63% | +68.50% | +93.41% | 2.85TCr | |
| Weighted average by Cap. | +1.04% | -2.34% | +89.43% | +121.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 391.1Cr 337.4Cr 317.84Cr 289.59Cr 541.29Cr 37TCr 545.35Cr 3.76TCr 1.46TCr 19TCr 1.47TCr 1.44TCr 62TCr | 400.08Cr 345.15Cr 325.13Cr 296.24Cr 553.71Cr 38TCr 557.87Cr 3.85TCr 1.49TCr 19TCr 1.5TCr 1.47TCr 63TCr |
| Net income | 16Cr 14Cr 13Cr 12Cr 22Cr 1.53TCr 23Cr 156.2Cr 61Cr 784.11Cr 61Cr 60Cr 2.58TCr | 43Cr 37Cr 35Cr 32Cr 59Cr 4.04TCr 60Cr 411.49Cr 159.7Cr 2.07TCr 160.6Cr 157.09Cr 6.79TCr |
| Net Debt | 211.22Cr 182.22Cr 171.66Cr 156.4Cr 292.34Cr 20TCr 294.53Cr 2.03TCr 788.71Cr 10TCr 793.17Cr 775.82Cr 34TCr | 163.07Cr 140.68Cr 132.52Cr 120.74Cr 225.69Cr 15TCr 227.38Cr 1.57TCr 608.9Cr 7.88TCr 612.34Cr 598.95Cr 26TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/26/03 | $291.08 | +3.09% | 3,43,886 |
| 01/26/01 | $282.34 | -2.05% | 7,05,710 |
| 31/26/31 | $288.24 | -1.12% | 10,86,241 |
| 28/26/28 | $291.50 | -1.66% | 6,59,870 |
| 27/26/27 | $296.41 | +0.44% | 9,01,386 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRL Stock
Select your edition
All financial news and data tailored to specific country editions
















